**Appendix 1: Impact of Florida’s PDMP and Pill Mill Law on Monthly Outcomes at 18 Months of Follow-up.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Low-Risk PrescribersN=36,939 | High-Risk PrescribersN=1,526 | Subset of High-Risk Prescribers |
|  | High-PrescriptionN=196 | High-PatientN=343 |
|  Comparative Change in Levels |  |  |  |  |
|  Opioid Patients, N | -6062(-14882,2758) | -2232(-4831,367) | 206(-329,741) | 312(-532,1157) |
|  Opioid Prescriptions, % of all prescriptions | -0.17(-0.47,0.12) | 0.08(-0.37,0.53) | 0.42(-0.72,1.57) | 0.34(-0.56,1.23) |
|  Opioid Patients, % of all patients | -0.39(-0.97,0.19) | 0.12(-0.77,1.01) | 0.59(-0.81,1.99) | 0.23(-1.03,1.49) |
|  Morphine Equivalent Dose, mg | -0.08(-2.41,2.26) | 0.22(-1.17,1.62) | 0.29(-1.07,1.65) | -1.22(-2.51,0.07) |
|  Total Opioid Volume, kg | 0.48(-5.90,6.86) | -1.79(-10.35,6.77) | 0.44(-1.67,2.55) | -0.30(-4.15,3.56) |
|  Days’ Supply | -0.11(-0.55,0.32) | 0.06(-0.04,0.16) | -0.03(-0.23,0.16) | 0.10(-0.03,0.23) |
|  Opioid Prescriptions, N | -6977(-16773,2819) | -1098(-6302,4105) | 261(-828,1351) | 479(-1342,2299) |
|  Comparative Change in Monthly Trends |  |  |  |  |
|  Opioid Patients, N | 871\*\*(49,1693) | -370(-1047,307) | -49(-99,1) | -140\*\*(-220,-61) |
|  Opioid Prescriptions, % of all prescriptions | 0.00(-0.02,0.03) | -0.02(-0.07,0.02) | 0.04(-0.07,0.15) | 0.08(-0.00,0.16) |
|  Opioid Patients, % of all patients | 0.01(-0.04,0.07) | -0.02(-0.10,0.07) | 0.10(-0.03,0.23) | 0.08(-0.03,0.20) |
|  Morphine Equivalent Dose, mg | 0.02(-0.25,0.28) | -0.55\*\*(-0.69,-0.41) | -0.30\*\*(-0.42,-0.17) | -0.70\*\*(-0.82,-0.58) |
|  Total Opioid Volume, kg | 1.00\*\*(0.40,1.60) | -2.89\*\*(-3.69,-2.08) | -0.48\*\*(-0.68,-0.28) | -1.57\*\*(-1.93,-1.21) |
|  Days’ Supply | -0.05(-0.10,0.00) | 0.00(-0.00,0.01) | -0.05\*\*(-0.07,-0.03) | -0.04\*\*(-0.05,-0.02) |
|  Opioid Prescriptions, N | 885(-35,1805) | -650\*\*(-1139,-161) | -107\*(-209,-4) | -283\*\*(-454,-112) |

\*P<0.05 \*\*P<0.01

Source: IMS Health Lifelink LRx Data, 2010-2012

**Appendix 2: Impact of Florida’s PDMP and Pill Mill Law on Monthly Outcomes at 6 Months of Follow-up.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Low-Risk PrescribersN=36,939 | High-Risk PrescribersN=1,526 | Subset of High-Risk Prescribers |
|  | High-PrescriptionN=196 | High-PatientN=343 |
|  Comparative Change in Levels |  |  |  |  |
|  Opioid Patients, N | -4344(-13901,5213) | -2232(-4831,367) | -447(-1143,249) | -0.35(-1.66,0.96) |
|  Opioid Prescriptions, % of all prescriptions | -0.04(-0.28,0.19) | -0.05(-0.49,0.39) | 0.68(-0.23,1.59) | -5.00\*(-9.60,-0.41) |
|  Opioid Patients, % of all patients | -0.19(-0.47,0.09) | 0.20(-0.14,0.53) | 1.10(-0.27,2.47) | -0.07(-0.23,0.08) |
|  Morphine Equivalent Dose, mg | 0.56\*\*(0.29,0.82) | -0.49(-1.29,0.31) | -0.61(-1.52,0.30) | -1679(-3551,193) |
|  Total Opioid Volume, kg | -0.12(-7.57,7.33) | -8.64(-18.63,1.34) | -1.99(-4.16,0.18) | -799(-1975,377) |
|  Days’ Supply | 0.01(-0.27,0.28) | 0.08(-0.01,0.17) | -0.15(-0.35,0.05) | 0.36(-0.37,1.09) |
|  Opioid Prescriptions, N | -4654(-18402,9093) | -3899(-9708,1911) | -917(-2040,206) | 0.17(-0.88,1.22) |
|  Comparative Change in Monthly Trends |  |  |  |  |
|  Opioid Patients, N | -327(-2944,2289) | -370(-1046,306) | 139(-51,329) | 95(-226,417) |
|  Opioid Prescriptions, % of all prescriptions | -0.03(-0.09,0.04) | -0.15\*(-0.27,-0.03) | -0.18(-0.43,0.07) | 0.04(-0.16,0.23) |
|  Opioid Patients, % of all patients | -0.04(-0.10,0.03) | -0.24\*\*(-0.32,-0.17) | 0.02(-0.36,0.39) | -0.05(-0.34,0.24) |
|  Morphine Equivalent Dose, mg | -0.15\*\*(-0.21,-0.10) | -0.72\*\*(-0.93,-0.50) | -0.27\*(-0.52,-0.02) | -1.22\*\*(-1.58,-0.86) |
|  Total Opioid Volume, kg | -0.94(-2.98,1.10) | -4.63\*\*(-7.23,-2.03) | -0.16(-0.72,0.41) | -1.97\*\*(-3.16,-0.77) |
|  Days’ Supply | -0.06(-0.14,0.01) | 0.01(-0.01,0.03) | 0.02(-0.02,0.07) | 0.02(-0.03,0.06) |
|  Opioid Prescriptions, N | -604(-4369,3161) | -797(-2311,716) | 90(-202,382) | -112(-600,376) |

\*P<0.05 \*\*P<0.01

Source: IMS Health Lifelink LRx Data, 2010-2012

**Appendix 3: Changes in opioid concentration and high-risk status following policy implementation by thresholds in Florida**

|  |  |  |  |
| --- | --- | --- | --- |
| Threshold to define High-Risk group | Being in High-Risk group in the post period | Concentration of total opioid volume among High-Risk group | Concentration of opioid prescriptions among High-Risk group |
| Pre | Post | Pre | Post |
| Top 1% | 77.97% | 35.03% | 35.14% | 15.74% | 16.59% |
| Top 3% | 82.92% | 56.50% | 57.09% | 30.60% | 31.91% |
| Top 5% | 83.09% | 66.59% | 67.30% | 39.99% | 41.36% |
| Top 10% | 83.24% | 78.42% | 78.81% | 53.85% | 54.99% |
| Top 20% | 85.31% | 88.37% | 88.39% | 69.91% | 70.45% |
| Top 25% | 86.04% | 90.79% | 90.67% | 75.13% | 75.43% |

Source: IMS Health Lifelink LRx Data, 2010-2012